Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Letrozole
Accession Number
DB01006  (APRD01066)
Type
Small Molecule
Groups
Approved, Investigational
Description

Letrozole (INN, trade name Femara®) is an oral non-steroidal aromatase inhibitor that has been introduced for the adjuvant treatment of hormonally-responsive breast cancer

Estrogens are produced by the conversion of androgens through the activity of the aromatase enzyme. Letrozole blocks the production of estrogens in this way by competitive, reversible binding to the heme of its cytochrome P450 unit. It is important to note that letrozole does not decrease the production of mineralocorticoids or corticosteroids. In contrast, the antiestrogenic action of tamoxifen, the major medical therapy prior to the arrival of aromatase inhibitors, is due to its interfering with the estrogen receptor, rather than inhibiting estrogen production. Side effects include signs and symptoms of hypoestrogenism. There is concern that long term use may lead to osteoporosis, which is why prescriptions of Letrozole are often accompanied by prescriptions of osteoporosis-fighting medication such as Fosamax. Letrozole has shown to reduce estrogen levels by 98 percent while raising testosterone levels. The anti-estrogen action of letrozole is preferred by athletes and bodybuilders for use during a steroid cycle to reduce bloating due to excess water retention and prevent the formation of gynecomastia related breast tissue that is a side effect of some anabolic steroids. Usage above 2.5 mg/day is known to potentially temporarily kill sex drive. Above 5mg/day for extended periods may cause kidney problems.

Letrozole has also been shown to delay the fusing of the growth plates in adolescents. This may boost the effectiveness of growth hormone, and thus Letrozole is used to treat adolescents and children with short stature.

Structure
Thumb
Synonyms
  • Letrozol
  • Letrozole
External IDs
CGS 20267 / CGS-20267
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Co LetrozoleTabletOralCobalt LaboratoriesNot applicableNot applicableCanada
FemaraTablet, film coated2.5 mg/1OralNovartis Pharmaceuticals Corporation1997-07-31Not applicableUs
FemaraTablet, film coated2.5 mg/1OralPhysicians Total Care, Inc.2005-02-10Not applicableUs
Femara 2.5mgTabletOralNovartis1997-09-02Not applicableCanada
LetrozoleTablet2.5 mgOralTEVA Canada Limited2010-04-282013-12-10Canada
LetrozoleTablet2.5 mgOralPro Doc Limitee2013-02-14Not applicableCanada
LetrozoleTablet2.5 mgOralActavis Pharma Company2010-04-282018-06-18Canada
LetrozoleTablet2.5 mgOralMeliapharm Inc2011-08-292014-06-25Canada
Letrozole SunTabletOralTaro Pharmaceuticals, Inc.Not applicableNot applicableCanada
Letrozole TabletsTabletOralFresenius KabiNot applicableNot applicableCanada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-letrozole Tablets USPTabletOralAccel Pharma IncNot applicableNot applicableCanada
Ach-letrozoleTabletOralAccord Healthcare Inc2010-05-03Not applicableCanada
Ag-letrozoleTabletOralAngita Pharma Inc.Not applicableNot applicableCanada
Apo-letrozoleTabletOralApotex Corporation2012-06-11Not applicableCanada
Auro-letrozoleTabletOralAuro Pharma Inc2013-06-122015-04-24Canada
Bio-letrozoleTabletOralBiomed Pharma2013-02-12Not applicableCanada
Ccp-letrozoleTabletOralCellchem Pharmaceuticals Inc.2017-07-24Not applicableCanada
Dom-letrozoleTabletOralDominion PharmacalNot applicableNot applicableCanada
Ipg-letrozoleTabletOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-letrozoleTabletOralJamp Pharma Corporation2011-09-30Not applicableCanada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Kisqali Femara Co-packLetrozole (2.5 mg/1) + Ribociclib (200 mg/1)OralNovartis Pharmaceuticals Corporation2017-05-04Not applicableUs
Kisqali Femara Co-packLetrozole (2.5 mg/1) + Ribociclib (200 mg/1)OralNovartis Pharmaceuticals Corporation2017-05-04Not applicableUs
Kisqali Femara Co-packLetrozole (2.5 mg/1) + Ribociclib (200 mg/1)OralNovartis Pharmaceuticals Corporation2017-05-04Not applicableUs
Categories
UNII
7LKK855W8I
CAS number
112809-51-5
Weight
Average: 285.3027
Monoisotopic: 285.101445377
Chemical Formula
C17H11N5
InChI Key
HPJKCIUCZWXJDR-UHFFFAOYSA-N
InChI
InChI=1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H
IUPAC Name
4-[(4-cyanophenyl)(1H-1,2,4-triazol-1-yl)methyl]benzonitrile
SMILES
N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N

Pharmacology

Indication

For the extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy. Also for first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. Also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy.

Associated Conditions
Pharmacodynamics

Letrozole is an aromatase inhibitor used in the treatment of breast cancer. Aromatase inhibitors work by inhibiting the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization. As breast tissue is stimulated by estrogens, decreasing their production is a way of suppressing recurrence of the breast tumor tissue.

Mechanism of action

Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system; it inhibits the conversion of androgens to estrogens. In adult nontumor- and tumorbearing female animals, letrozole is as effective as ovariectomy in reducing uterine weight, elevating serum Leuteinizing hormone (LH), and causing the regression of estrogen-dependent tumors. In contrast to ovariectomy, treatment with letrozole does not lead to an increase in serum (folicile stimulating hormone (FSH). Letrozole selectively inhibits gonadal steroidogenesis but has no significant effect on adrenal mineralocorticoid or glucocorticoid synthesis.

TargetActionsOrganism
ACytochrome P450 19A1
antagonist
Humans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Rapidly and completely absorbed. Absorption is not affected by food.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Primarily hepatic via CYP3A4 and CYP2A6. Letrozole inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues. It is metabolized slowly to an inactive metabolite whose glucuronide conjugate is excreted renally, representing the major clearance pathway.

Route of elimination
Not Available
Half life

2 days

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe metabolism of Letrozole can be increased when combined with Abatacept.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Letrozole.
AcipimoxThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Letrozole is combined with Acipimox.
AdalimumabThe metabolism of Letrozole can be increased when combined with Adalimumab.
AfelimomabThe metabolism of Letrozole can be increased when combined with Afelimomab.
Alendronic acidThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Letrozole.
Aluminium clofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Letrozole is combined with Aluminium clofibrate.
AmiodaroneThe metabolism of Letrozole can be decreased when combined with Amiodarone.
AmphetamineThe metabolism of Letrozole can be decreased when combined with Amphetamine.
Amphotericin BThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Letrozole.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Take without regard to meals. Food slows absorption without decreasing the quantity absorbed.

References

Synthesis Reference

Peter MacDonald, Ettore Bigatti, Pierluigi Rossetto, Zvi Harel, "Process for the preparation of letrozole." U.S. Patent US20070066831, issued March 22, 2007.

US20070066831
General References
  1. Tulandi T, Martin J, Al-Fadhli R, Kabli N, Forman R, Hitkari J, Librach C, Greenblatt E, Casper RF: Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril. 2006 Jun;85(6):1761-5. Epub 2006 May 2. [PubMed:16650422]
External Links
Human Metabolome Database
HMDB0015141
KEGG Drug
D00964
KEGG Compound
C08163
PubChem Compound
3902
PubChem Substance
46504610
ChemSpider
3765
BindingDB
13061
ChEBI
6413
ChEMBL
CHEMBL1444
Therapeutic Targets Database
DAP000626
PharmGKB
PA450196
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Letrozole
ATC Codes
L02BG04 — Letrozole
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
FDA label
Download (112 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceBreast Cancer1
0CompletedTreatmentInfertility / Polycystic Ovaries Syndrome2
0Not Yet RecruitingTreatmentBreast Cancer1
0Not Yet RecruitingTreatmentMalignant Neoplasm of Female Breast1
0RecruitingBasic ScienceBreast Cancer1
0RecruitingBasic ScienceNeoplasms, Brain1
0RecruitingBasic ScienceOvarian Cancer1
0RecruitingTreatmentBreast Cancer1
0RecruitingTreatmentEndometrial Endometrioid Adenocarcinoma1
0RecruitingTreatmentEstrogen Receptor-Positive Breast Cancer1
0TerminatedTreatmentBreast Cancer1
1Active Not RecruitingOtherAdvanced Breast Cancer1
1Active Not RecruitingTreatmentAdvanced Malignant Solid Neoplasm / Breast Cancer / Estrogen Receptor Positive / HER2/Neu Positive / One to five years postmenopausal / Premenopausal / Progesterone Receptor Positive / Recurrent Breast Carcinoma / Refractory Breast Carcinoma / Refractory Hormone Receptor Positive Breast Carcinoma / Stage IIIA Breast Cancer AJCC v7 / Stage IIIB Breast Cancer AJCC v7 / Stage IIIC Breast Cancer AJCC v7 / Stage IV Breast Cancer AJCC v6 and v7 / Tumors, Solid1
1Active Not RecruitingTreatmentBreast Cancer1
1Active Not RecruitingTreatmentCancer, Advanced / Lung Cancer Non-Small Cell Cancer (NSCLC) / Mesothelioma, Malignant / Metastatic Breast Cancer / Metastatic Cancers / Non-Hodgkin's Lymphoma (NHL)1
1Active Not RecruitingTreatmentCastration Resistant Prostate Cancer (CRPC) / Hormone Receptor Positive Advanced Breast Cancer / Human Epidermal Receptor 2 Negative Advanced Breast Cancer / Metastatic Breast Cancer1
1Active Not RecruitingTreatmentEstrogen Receptor-Positive Breast Cancer / HER2-Negative Breast Cancer / Invasive Ductal Breast Carcinoma / Progesterone Receptor-positive Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
1Active Not RecruitingTreatmentHormone Receptor Positive, HER2-negative, Advanced Breast Cancer1
1Active Not RecruitingTreatmentMetastatic or Locally-advanced Unresectable Breast Cancer1
1Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL) / Non-Hodgkin's Lymphoma, Solid Cancers / Solid Cancers1
1CompletedNot AvailableHealthy Volunteers2
1CompletedBasic ScienceTumors, Solid1
1CompletedOtherAdvanced or Metastatic Breast Cancer1
1CompletedPreventionHealthy, no Evidence of Disease / Lobular Breast Carcinoma In Situ1
1CompletedTreatmentBreast Cancer3
1CompletedTreatmentBreast Cancer / Metastatic Breast Cancer, Locally Advanced Breast Cancer1
1CompletedTreatmentFocus of Study1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentMcCune Albright Syndrome / Polyostotic Fibrous Dysplasia / Puberty, Precocious1
1CompletedTreatmentMetastatic Breast Cancer1
1Not Yet RecruitingOtherUterine Leiomyomas1
1Not Yet RecruitingTreatmentAnatomic Stage III Breast Cancer AJCC v8 / Anatomic Stage IIIA Breast Cancer AJCC v8 / Anatomic Stage IIIB Breast Cancer AJCC v8 / Anatomic Stage IIIC Breast Cancer AJCC v8 / Anatomic Stage IV Breast Cancer AJCC v8 / Estrogen Receptor Positive / HER2/Neu Negative / Invasive Breast Carcinoma / Prognostic Stage III Breast Cancer AJCC v8 / Prognostic Stage IIIA Breast Cancer AJCC v8 / Prognostic Stage IIIB Breast Cancer AJCC v8 / Prognostic Stage IIIC Breast Cancer AJCC v8 / Prognostic Stage IV Breast Cancer AJCC v8 / Recurrent Breast Carcinoma1
1Not Yet RecruitingTreatmentBreast Neoplasm Female1
1RecruitingOtherHealthy Volunteers1
1RecruitingTreatmentBreast Cancer3
1RecruitingTreatmentBreast Cancer / Tumors, Solid1
1RecruitingTreatmentNeoplasms, Breast1
1RecruitingTreatmentNeoplasms / Neoplasms, Breast1
1TerminatedTreatmentBreast Cancer2
1TerminatedTreatmentEstrogen Receptor-Positive Breast Cancer / HER2-Negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer1
1WithdrawnTreatmentSymptomatic or Large Uterine Fibroids1
1, 2Active Not RecruitingTreatmentBreast Cancer1
1, 2Active Not RecruitingTreatmentMetastatic Breast Cancer1
1, 2CompletedNot AvailableBreast Cancer1
1, 2CompletedTreatmentAndrogen Deficiency / BMI >30 kg/m2 / Insulin Resistance / Metabolic Diseases / Type 2 Diabetes Mellitus1
1, 2CompletedTreatmentBreast Cancer2
1, 2CompletedTreatmentOvarian Stimulation1
1, 2Not Yet RecruitingTreatmentHer2-Positive Breast Cancer / Metastatic Breast Cancer / One to five years postmenopausal1
1, 2RecruitingTreatmentAdvanced Breast Cancer1
1, 2RecruitingTreatmentAnatomic Stage I Breast Cancer AJCC v8 / Anatomic Stage IA Breast Cancer AJCC v8 / Anatomic Stage IB Breast Cancer AJCC v8 / Anatomic Stage II Breast Cancer AJCC v8 / Anatomic Stage IIA Breast Cancer AJCC v8 / Anatomic Stage IIB Breast Cancer AJCC v8 / Anatomic Stage III Breast Cancer AJCC v8 / Anatomic Stage IIIA Breast Cancer AJCC v8 / Anatomic Stage IIIB Breast Cancer AJCC v8 / Anatomic Stage IIIC Breast Cancer AJCC v8 / Anatomic Stage IV Breast Cancer AJCC v8 / Estrogen Receptor Positive / HER2/Neu Negative / MKI67 Positive / One to five years postmenopausal / Prognostic Stage I Breast Cancer AJCC v8 / Prognostic Stage IA Breast Cancer AJCC v8 / Prognostic Stage IB Breast Cancer AJCC v8 / Prognostic Stage IIA Breast Cancer AJCC v8 / Prognostic Stage IIB Breast Cancer AJCC v8 / Prognostic Stage III Breast Cancer AJCC v8 / Prognostic Stage IIIA Breast Cancer AJCC v8 / Prognostic Stage IIIB Breast Cancer AJCC v8 / Prognostic Stage IIIC Breast Cancer AJCC v8 / Prognostic Stage IV Breast Cancer AJCC v81
1, 2RecruitingTreatmentBreast Cancer4
1, 2RecruitingTreatmentHer2-Positive Breast Cancer / Metastatic Breast Cancer1
1, 2SuspendedTreatmentEarly Breast Cancer / Estrogen Receptor Positive / HER2/Neu Negative / Invasive Breast Carcinoma / Multifocal Breast Carcinoma / One to five years postmenopausal / Progesterone Receptor Positive / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage III Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
1, 2TerminatedTreatmentBreast Cancer1
2Active Not RecruitingBasic ScienceBreast Cancer1
2Active Not RecruitingPreventionBreast Cancer / Osteoporosis1
2Active Not RecruitingTreatmentAdvanced, Persistent, or Recurrent Endometrial Cancer1
2Active Not RecruitingTreatmentBreast Cancer8
2Active Not RecruitingTreatmentBreast Cancer / Cancer of the Breast / Neoplasms, Breast1
2Active Not RecruitingTreatmentBreast Cancer / Carcinoma, Breast / Tumors, Breast1
2Active Not RecruitingTreatmentBreast Cancer / Hormone Receptor Positive Tumor / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast1
2Active Not RecruitingTreatmentCongenital Adrenal Hyperplasia (CAH) / Growth Disorders1
2Active Not RecruitingTreatmentEndometrial Cancer3
2Active Not RecruitingTreatmentEstrogen Receptor Positive / One to five years postmenopausal / RB1 Positive / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Recurrent Uterine Corpus Carcinoma1
2Active Not RecruitingTreatmentEstrogen Receptor-Positive Breast Cancer / HER2-Negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Recurrent Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
2Active Not RecruitingTreatmentFibrolamellar Carcinoma / Fibrolamellar Liver Cancer1
2Active Not RecruitingTreatmentHormone Receptor Positive Breast Cancer1
2Active Not RecruitingTreatmentMalignant Ovarian Mixed Epithelial Tumor / Ovarian Endometrioid Adenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Serous Surface Papillary Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Ovarian Germ Cell Tumor / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Ovarian Carcinoma1
2Active Not RecruitingTreatmentMetastatic Breast Cancer2
2Active Not RecruitingTreatmentNeoadjuvant Operable Breast Cancer1
2Active Not RecruitingTreatmentNeoplasms, Breast2
2Active Not RecruitingTreatmentReccurent/Metastatic Solid Tumor Disease1
2CompletedDiagnosticBreast Cancer1
2CompletedPreventionBreast Cancer5
2CompletedSupportive CareDuctal Carcinoma In Situ / Early Breast Cancer / Estrogen Receptor-Positive Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
2CompletedSupportive CareEarly Breast Cancer / Joint Pain / Musculoskeletal Complications / Pain / Recurrent Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
2CompletedTreatmentAnatomic Stage IV Breast Cancer AJCC v8 / Breast Cancer / Estrogen Receptor Positive / KIT Positive / One to five years postmenopausal / PDGFR Positive / Progesterone Receptor Positive / Prognostic Stage IV Breast Cancer AJCC v81
2CompletedTreatmentBreast Cancer17
2CompletedTreatmentEndocrine Sensitive HER2+/HR+ Breast Cancer1
2CompletedTreatmentEndometrial Cancer2
2CompletedTreatmentEstrogen Receptor-negative Breast Cancer / Estrogen Receptor-Positive Breast Cancer / Her2-Positive Breast Cancer / Progesterone Receptor-negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer1
2CompletedTreatmentHighly Endocrine Responsive Operable Breast Cancer1
2CompletedTreatmentInfertility2
2CompletedTreatmentInvasive Breast Cancer1
2CompletedTreatmentLeiomyosarcomas1
2CompletedTreatmentLymphangioleiomyomatosis1
2CompletedTreatmentMetastatic Breast Cancer6
2CompletedTreatmentNeoplasms, Breast5
2CompletedTreatmentNeoplasms / Neoplasms, Breast1
2CompletedTreatmentOvarian Response1
2CompletedTreatmentPostmenopausal Women With Advanced Breast Cancer3
2CompletedTreatmentPregnancy1
2CompletedTreatmentRecurrent and Metastatic Endometrial Cancer1
2CompletedTreatmentSevere and Recurrent Endometriosis1
2Not Yet RecruitingOtherHR+ HER2 Breast Cancer1
2Not Yet RecruitingPreventionEndometriosis / Ovarian Hyperstimulation1
2Not Yet RecruitingTreatmentAnovulatory cycle / Polycystic Ovaries Syndrome1
2Not Yet RecruitingTreatmentBreast Cancer1
2Not Yet RecruitingTreatmentBreast Cancer / Breast Cancer Stage II / Breast Cancer Stage III / Her2-Positive Breast Cancer / Malignant Neoplasm of Female Breast1
2Not Yet RecruitingTreatmentBreast Diseases / Her2-Positive Breast Cancer / Hormone Receptor Positive Malignant Neoplasm of Breast / Hormone Receptor Positive Tumor / Malignant Neoplasm of Female Breast / Metastatic Breast Cancer2
2Not Yet RecruitingTreatmentMetastatic Breast Cancer1
2Not Yet RecruitingTreatmentOvarian Cancer1
2RecruitingBasic ScienceBreast Cancer1
2RecruitingOtherBreast Cancer1
2RecruitingTreatmentAbortions spontaneous / Missed Abortion1
2RecruitingTreatmentAdvanced Breast Cancer / Breast Cancer / Hormone Receptor Positive Tumor / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast1
2RecruitingTreatmentAnatomic Stage IV Breast Cancer AJCC v8 / Estrogen Receptor Positive / HER2/Neu Negative / Metastatic Breast Carcinoma / Metastatic Malignant Neoplasm in the Bone / Progesterone Receptor Positive / Prognostic Stage IV Breast Cancer AJCC v81
2RecruitingTreatmentBreast Cancer12
2RecruitingTreatmentBreast Cancer / Cancer of the Breast / Carcinoma, Breast1
2RecruitingTreatmentBreast Cancer / Cancer of the Breast / Carcinoma, Breast / Malignant Tumor of Breast1
2RecruitingTreatmentBreast Cancer / Estrogen Receptor Positive Tumor / Her2-Positive Breast Cancer1
2RecruitingTreatmentBreast Cancer / Hormone Receptor Positive Tumor1
2RecruitingTreatmentBreast Cancer / Invasive Breast Cancer2
2RecruitingTreatmentEarly Breast Cancer / Hormone Receptor Positive Tumor1
2RecruitingTreatmentEarly-Stage Breast Carcinoma / Estrogen Receptor Positive Tumor1
2RecruitingTreatmentEarly-Stage Breast Carcinoma / Hormone Receptor Positive Tumor1
2RecruitingTreatmentEndometrial Cancer1
2RecruitingTreatmentEndometrial Cancer / Ovarian Cancer1
2RecruitingTreatmentEndometrial Carcinoma / Malignant Neoplasms of Female Genital Organs1
2RecruitingTreatmentEstrogen Receptor Negative / Estrogen Receptor Positive / HER2/Neu Negative / Progesterone Receptor Negative / Progesterone Receptor Positive / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma1
2RecruitingTreatmentEstrogen Receptor Positive / HER2/Neu Negative / Metastatic Breast Carcinoma / One to five years postmenopausal / Recurrent Breast Carcinoma / Stage IV Breast Cancer1
2RecruitingTreatmentEstrogen Receptor-Positive Breast Cancer / HER2/Neu Negative / Stage IV Breast Cancer AJCC v6 and v71
2RecruitingTreatmentHer2-Positive Breast Cancer / Metastatic Breast Cancer1
2RecruitingTreatmentLow Grade Endometrial Stromal Sarcoma1
2RecruitingTreatmentLow Grade Serous Carcinoma1
2RecruitingTreatmentMetastatic Breast Cancer4
2RecruitingTreatmentNeoplasms, Breast3
2RecruitingTreatmentUterine Cervical Neoplasms1
2RecruitingTreatmentTo Evaluate Letrozole as a Modality for Minimal Ovarian Stimulation in ICSI Cycles 1
2TerminatedNot AvailableEarly Breast Cancer1
2TerminatedTreatmentAdvanced Breast Cancer (Phase 1b) / Early Breast Cancer (Phase 2)1
2TerminatedTreatmentBreast Cancer8
2TerminatedTreatmentCarcinoma, Breast1
2TerminatedTreatmentEndocrine Breast Diseases / Neoplasms Metastasis / Neoplasms, Breast1
2TerminatedTreatmentEstrogen Receptor-Positive Breast Cancer / HER2-Negative Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
2TerminatedTreatmentFallopian Tube Cancer / Malignant Peritoneal Neoplasm / Ovarian Cancer1
2TerminatedTreatmentHormone-sensitive Metastatic Breast Cancer1
2TerminatedTreatmentLeiomyosarcomas / Uterine Neoplasms1
2TerminatedTreatmentMedical Abortion, Complete or Unspecified, Without Complication1
2TerminatedTreatmentNeoplasms, Breast1
2Unknown StatusPreventionBreast Cancer / One to five years postmenopausal1
2Unknown StatusTreatmentBreast Cancer2
2Unknown StatusTreatmentBreast Cancer / Hormone-Sensitive Breast Cancer1
2Unknown StatusTreatmentER Positive, HER2 Negative Breast Cancer1
2WithdrawnTreatmentBreast Cancer2
2WithdrawnTreatmentBreast Cancer / Breast Cancer Stage II / Breast Cancer Stage III1
2WithdrawnTreatmentFallopian Tube Cancer / Malignant Peritoneal Neoplasm / Ovarian Cancer1
2, 3Active Not RecruitingNot AvailableHealthy Volunteers / Idiopathic Hypogonadotropic Hypogonadism / Olfacto genital dysplasia1
2, 3Active Not RecruitingTreatmentHormone Receptor Positive HER-2 Negative Breast Cancer / HR+ HER2 Negative Breast Cancer1
2, 3Active Not RecruitingTreatmentInflammatory carcinoma of the breast / Invasive Ductal Breast Carcinoma / Mucinous Breast Cancer / Tubular Breast Carcinoma1
2, 3Active Not RecruitingTreatmentLow Grade Ovarian Serous Adenocarcinoma / Micropapillary Serous Carcinoma / Ovarian Serous Adenocarcinoma / Primary Peritoneal Serous Adenocarcinoma / Recurrent Low Grade Ovarian Serous Adenocarcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Recurrent Primary Peritoneal Serous Adenocarcinoma1
2, 3Active Not RecruitingTreatmentUterine Malignancies1
2, 3CompletedOtherPolycystic Ovaries Syndrome1
2, 3CompletedTreatmentAbortions spontaneous1
2, 3CompletedTreatmentBreast Cancer1
2, 3CompletedTreatmentComplete Miscarriage1
2, 3CompletedTreatmentConstitutional Delay of Growth and Puberty1
2, 3CompletedTreatmentInfertility2
2, 3CompletedTreatmentMetastatic Breast Cancer1
2, 3CompletedTreatmentThe Efficacy of Aromatase Inhibitor vs. Gonadotrpins Releasing Hormone Agonists in Treating Premenopausal Women With Uterine Adenomyosis1
2, 3Not Yet RecruitingTreatmentBreast Cancer1
2, 3Not Yet RecruitingTreatmentBreast Cancer / Cancer treatment / Endocrine Breast Diseases1
2, 3RecruitingPreventionBreast Cancer1
2, 3TerminatedTreatmentBreast Cancer1
3Active Not RecruitingPreventionBrca1 Mutation Carrier / Brca2 Mutation Carrier / Breast Cancer / Hereditary Breast/Ovarian Cancer (brca1, brca2)1
3Active Not RecruitingTreatmentAdvanced Metastatic Breast Cancer1
3Active Not RecruitingTreatmentAdvanced Metastatic Breast Cancer / Advanced, Metastatic Breast Cancer1
3Active Not RecruitingTreatmentAdvanced, Metastatic Breast Cancer1
3Active Not RecruitingTreatmentBreast Adenocarcinoma / Estrogen Receptor and/or Progesterone Receptor Positive / HER2/Neu Negative / Stage IA Breast Cancer / Stage IA Breast Cancer AJCC v7 / Stage IB Breast Cancer / Stage IB Breast Cancer AJCC v7 / Stage IIA Breast Cancer / Stage IIA Breast Cancer AJCC v6 and v7 / Stage IIB Breast Cancer / Stage IIB Breast Cancer AJCC v6 and v7 / Stage IIIB Breast Cancer / Stage IIIB Breast Cancer AJCC v71
3Active Not RecruitingTreatmentBreast Cancer12
3Active Not RecruitingTreatmentDuctal Breast Carcinoma In Situ / Estrogen Receptor and/or Progesterone Receptor Positive / Estrogen Receptor Positive / HER2/Neu Negative / Invasive Breast Carcinoma / Multicentric Breast Carcinoma / Multifocal Breast Carcinoma / Progesterone Receptor Positive / Synchronous Bilateral Breast Carcinoma1
3Active Not RecruitingTreatmentEstrogen Receptor Positive / Invasive Breast Carcinoma / One to five years postmenopausal / Progesterone Receptor Positive / Recurrent Breast Carcinoma / Stage III Breast Cancer AJCC v6 / Stage IIIB Breast Cancer / Stage IIIB Breast Cancer AJCC v7 / Stage IV Breast Cancer / Stage IV Breast Cancer AJCC v6 and v71
3Active Not RecruitingTreatmentMetastatic Breast Cancer2
3Active Not RecruitingTreatmentNeoplasms, Breast2
3CompletedPreventionBreast Cancer1
3CompletedPreventionNeoplasms, Breast / Osteoporosis1
3CompletedSupportive CareBreast Cancer / Osteoporosis1
3CompletedTreatmentAdvanced Breast Cancer (Female) / Advanced Breast Cancer Female1
3CompletedTreatmentAzoospermia, Nonobstructive / Oligozoospermia1
3CompletedTreatmentBMI >30 kg/m2 / Hypogonadotrophic Hypogonadism1
3CompletedTreatmentBone Loss / Breast Cancer1
3CompletedTreatmentBreast Cancer12
3CompletedTreatmentHormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women1
3CompletedTreatmentIdiopathic Short Stature (ISS)1
3CompletedTreatmentInfertility2
3CompletedTreatmentMalignant Neoplasm of Female Breast1
3CompletedTreatmentNeoplasms, Breast1
3CompletedTreatmentNeoplasms, Breast / Neoplasms, Hormone-Dependent1
3CompletedTreatmentOne to five years postmenopausal / Osteoporosis1
3CompletedTreatmentPolycystic Ovarian Syndrome1
3CompletedTreatmentPolycystic Ovaries Syndrome / Pregnancy1
3CompletedTreatmentPregnancy / Unexplained Infertility1
3CompletedTreatmentTranssexualism1
3CompletedTreatmentUnexplained Infertility1
3Not Yet RecruitingPreventionOvarian Hyperstimulation Syndrome1
3Not Yet RecruitingTreatmentAbdominal wall neoplasm / Fallopian Tube Neoplasms / Ovarian Neoplasm Epithelial1
3Not Yet RecruitingTreatmentAdvanced Breast Cancer1
3Not Yet RecruitingTreatmentCancer Metastatic1
3RecruitingTreatmentBreast Cancer5
3RecruitingTreatmentBreast Neoplasm Female1
3RecruitingTreatmentEstrogen Receptor Positive Breast Cancer / HER-2 Positive Breast Cancer1
3RecruitingTreatmentFemale Infertility1
3RecruitingTreatmentInduction of Ovulation1
3RecruitingTreatmentInfertility3
3RecruitingTreatmentLow Grade Ovarian Serous Adenocarcinoma / Primary Peritoneal Low Grade Serous Adenocarcinoma / Stage II Ovarian Cancer AJCC v8 / Stage IIA Ovarian Cancer AJCC v8 / Stage IIB Ovarian Cancer AJCC v8 / Stage III Ovarian Cancer AJCC v8 / Stage IIIA Ovarian Cancer AJCC v8 / Stage IIIA1 Ovarian Cancer AJCC v8 / Stage IIIA2 Ovarian Cancer AJCC v8 / Stage IIIB Ovarian Cancer AJCC v8 / Stage IIIC Ovarian Cancer AJCC v8 / Stage IV Ovarian Cancer AJCC v8 / Stage IVA Ovarian Cancer AJCC v8 / Stage IVB Ovarian Cancer AJCC v8 / TP53 Negative1
3RecruitingTreatmentMetastatic Breast Cancer1
3RecruitingTreatmentNeoadjuvant Therapy1
3RecruitingTreatmentPolycystic Ovaries Syndrome2
3RecruitingTreatmentSubfertility1
3TerminatedOtherBreast Cancer1
3TerminatedTreatmentNeoplasms Metastasis / Neoplasms, Breast1
3TerminatedTreatmentNeoplasms, Breast / Neoplasms, Hormone-Dependent2
3TerminatedTreatmentOperable Breast Neoplasms1
3Unknown StatusTreatmentBreast Cancer3
3WithdrawnTreatmentBreast Cancer1
4Active Not RecruitingPreventionFertility / Neoplasms, Breast1
4CompletedBasic ScienceFertility1
4CompletedDiagnosticESTROGENS/RIFAMPIN [VA Drug Interaction] / Ovarian Cysts / Ovulatory Dysfunction1
4CompletedPreventionBreast Cancer1
4CompletedPreventionOvarian Hyperstimulation Syndrome1
4CompletedTreatmentBreast Cancer5
4CompletedTreatmentHormono-depending Adjuvant Breast Cancer1
4CompletedTreatmentInfertility1
4CompletedTreatmentInfertility Indicated for ICSI1
4CompletedTreatmentInfertility / Polycystic Ovarian Syndrome1
4CompletedTreatmentInfertility / Polycystic Ovaries Syndrome1
4CompletedTreatmentLeiomyomas / Uterine Leiomyomas1
4CompletedTreatmentLocally Advanced Breast Cancer (LABC)1
4CompletedTreatmentLocally Advanced Metastatic Breast Cancer / Locally Advanced or Metastatic Breast Cancer / Metastatic Breast Cancer / Postmenopausal Women1
4Not Yet RecruitingTreatmentBreast Cancer1
4Not Yet RecruitingTreatmentFemale Infertility / IVF / Ovulatory Dysfunction / Polycystic Ovaries Syndrome1
4Not Yet RecruitingTreatmentInvestigative Techniques / Reproductive Techniques / Reproductive Techniques, Assisted1
4RecruitingHealth Services ResearchBMI >30 kg/m21
4RecruitingTreatmentAnovulatory cycle1
4RecruitingTreatmentEarly Breast Cancer1
4RecruitingTreatmentMetastatic Breast Cancer1
4RecruitingTreatmentNeoplasms, Breast1
4RecruitingTreatmentPolycystic Ovarian Syndrome1
4RecruitingTreatmentShort Stature1
4TerminatedTreatmentMetastatic Breast Cancer2
4TerminatedTreatmentNeoplasms, Breast1
4Unknown StatusTreatmentBreast Cancer1
4Unknown StatusTreatmentPoor Responders Undergoing IVF1
4Unknown StatusTreatmentIs to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients1
4WithdrawnTreatmentHER2/Neu Negative / Invasive Breast Carcinoma / One to five years postmenopausal / Stage 0 Breast Cancer / Stage IA Breast Cancer1
4WithdrawnTreatmentInfertility1
Not AvailableActive Not RecruitingNot AvailableBreast Cancer2
Not AvailableActive Not RecruitingTreatmentBreast Cancer / Infertility1
Not AvailableActive Not RecruitingTreatmentMale Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
Not AvailableActive Not RecruitingTreatmentNeoplasms, Breast1
Not AvailableCompletedNot AvailableBMI >30 kg/m21
Not AvailableCompletedNot AvailableBMI >30 kg/m2 / Breast Cancer / Joint Pain1
Not AvailableCompletedNot AvailableBreast Cancer1
Not AvailableCompletedNot AvailableBreast Cancer / Joint Pain / Pain1
Not AvailableCompletedNot AvailableInfertility1
Not AvailableCompletedNot AvailableJoint Pain1
Not AvailableCompletedBasic ScienceBreast Cancer1
Not AvailableCompletedHealth Services ResearchOvarian Follicle1
Not AvailableCompletedHealth Services ResearchPolycystic Ovaries Syndrome1
Not AvailableCompletedOtherHealthy Volunteers1
Not AvailableCompletedOtherInfertility1
Not AvailableCompletedPreventionBreast Cancer / Osteoporosis1
Not AvailableCompletedTreatmentBreast Cancer1
Not AvailableCompletedTreatmentEndometrial Carcinoma1
Not AvailableCompletedTreatmentEndometriosis1
Not AvailableCompletedTreatmentInfertility1
Not AvailableCompletedTreatmentInfertility Poly Cystic Ovary1
Not AvailableCompletedTreatmentMale Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
Not AvailableCompletedTreatmentPolycystic Ovaries Syndrome3
Not AvailableCompletedTreatmentPoor Responders1
Not AvailableEnrolling by InvitationNot AvailableBreast Cancer1
Not AvailableNo Longer AvailableNot AvailableAdvanced Breast Cancer (Female)1
Not AvailableNot Yet RecruitingTreatmentInduction of Abortion1
Not AvailableNot Yet RecruitingTreatmentInfertility1
Not AvailableNot Yet RecruitingTreatmentInfertility / Polycystic Ovaries Syndrome1
Not AvailableNot Yet RecruitingTreatmentIntrauterine Insemination / Unexplained Infertility1
Not AvailableRecruitingNot AvailableHR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer / HR+ HER2- Postmenopausal Advanced Breast Cancer1
Not AvailableRecruitingBasic ScienceBreast Cancer1
Not AvailableRecruitingBasic ScienceNeoplasms1
Not AvailableRecruitingTreatmentBreast Cancer1
Not AvailableRecruitingTreatmentFemale Infertility Due to Nonimplantation of Ovum1
Not AvailableRecruitingTreatmentInfertility / Intrauterine Insemination1
Not AvailableRecruitingTreatmentNeoplasms Metastasis / Neoplasms, Breast1
Not AvailableRecruitingTreatmentPolycystic Ovarian Syndrome / Subfertility1
Not AvailableUnknown StatusNot AvailableArthritis / Joint Pain / Neoplasms, Breast / Polymorphism, Genetic1
Not AvailableUnknown StatusNot AvailableArterial hypoxia / Breast Cancer1
Not AvailableUnknown StatusNot AvailableLow Responders / Mild to Moderate Male Factor Infertility / Primary Infertility / Secondary Infertility1
Not AvailableUnknown StatusTreatmentComplete Abortion1
Not AvailableUnknown StatusTreatmentInfertility2
Not AvailableUnknown StatusTreatmentPolycystic Ovarian Syndrome1
Not AvailableUnknown StatusTreatmentPolycystic Ovaries Syndrome2

Pharmacoeconomics

Manufacturers
  • Novartis pharmaceuticals corp
  • Mylan pharmaceuticals inc
Packagers
  • Kaiser Foundation Hospital
  • Novartis AG
  • Physicians Total Care Inc.
Dosage forms
FormRouteStrength
TabletOral
TabletOral2.5 mg
TabletOral2.5 mg/1
Tablet, coatedOral2.5 mg/1
Tablet, film coatedOral2.5 mg/1
Prices
Unit descriptionCostUnit
Femara 2.5 mg tablet16.87USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4978672No1990-12-182011-06-03Us
US8685980No2014-04-012030-05-25Us
US9193732No2015-11-242031-11-09Us
US8415355No2013-04-092031-02-19Us
US8324225No2012-12-042028-06-17Us
US9416136No2016-08-162029-08-20Us
US8962630No2015-02-242029-12-09Us
US9868739No2018-01-162031-11-09Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)184-185 °CNot Available
logP2.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0799 mg/mLALOGPS
logP1.86ALOGPS
logP2.94ChemAxon
logS-3.6ALOGPS
pKa (Strongest Basic)2.17ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area78.29 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity94.47 m3·mol-1ChemAxon
Polarizability29.59 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9965
Blood Brain Barrier+0.9737
Caco-2 permeable+0.6347
P-glycoprotein substrateNon-substrate0.8391
P-glycoprotein inhibitor INon-inhibitor0.8087
P-glycoprotein inhibitor IINon-inhibitor0.9147
Renal organic cation transporterNon-inhibitor0.5908
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6843
CYP450 1A2 substrateNon-inhibitor0.8374
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorInhibitor0.8993
CYP450 3A4 inhibitorInhibitor0.6451
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7027
Ames testNon AMES toxic0.6371
CarcinogenicityNon-carcinogens0.8926
BiodegradationNot ready biodegradable0.9864
Rat acute toxicity1.9916 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9261
hERG inhibition (predictor II)Non-inhibitor0.8817
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-001i-0090000000-0fbd577a32ff572f7368
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-001i-0190000000-dfcab9af789387521571
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-0390000000-dbc68fd6017abe6e8adc
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00kf-0490000000-c3fc389848a06a012234
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014l-0690000000-38ba597054b02b136ab6
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00kf-1980000000-13a8827cbc5c1b36a14f
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00kf-3940000000-e01d63313ef1cfa7477a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-9410000000-83b93aed0756bd41adaf
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-9100000000-d1757f8c218d5dcc4809
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0090000000-791121bd513899b7dfc0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0090000000-eb3996846ea4f036ccca
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-0390000000-a57ce4cfb24ba743c54b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-0950000000-303d99867511fe3a013b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-0930000000-77e720374927be5113ef
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-0920000000-4a93d8e76eb7d0d59481
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03du-0910000000-8ad9f37884e8686ef7ba
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03dr-2900000000-2274a3adb5e486f57001
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03dr-6900000000-74d56231c43250bc65ca
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-0490000000-7868daa9f0ec9ebda34a

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Benzonitriles / Triazoles / Heteroaromatic compounds / Nitriles / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Diphenylmethane / Benzonitrile / Heteroaromatic compound / 1,2,4-triazole / Azole / Azacycle / Organoheterocyclic compound / Nitrile / Carbonitrile / Organic nitrogen compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
nitrile, triazoles (CHEBI:6413)

Targets

Details
1. Cytochrome P450 19A1
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Oxygen binding
Specific Function
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name
CYP19A1
Uniprot ID
P11511
Uniprot Name
Aromatase
Molecular Weight
57882.48 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Ebert AD, Bartley J, David M, Schweppe KW: [Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis]. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51. [PubMed:14505258]
  3. Long BJ, Jelovac D, Handratta V, Thiantanawat A, MacPherson N, Ragaz J, Goloubeva OG, Brodie AM: Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J Natl Cancer Inst. 2004 Mar 17;96(6):456-65. [PubMed:15026471]
  4. Murphy MJ Jr: Molecular Action and Clinical Relevance of Aromatase Inhibitors. Oncologist. 1998;3(2):129-130. [PubMed:10388095]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name
CYP19A1
Uniprot ID
P11511
Uniprot Name
Aromatase
Molecular Weight
57882.48 Da
References
  1. Azria D, Larbouret C, Cunat S, Ozsahin M, Gourgou S, Martineau P, Evans DB, Romieu G, Pujol P, Pelegrin A: Letrozole sensitizes breast cancer cells to ionizing radiation. Breast Cancer Res. 2005;7(1):R156-63. doi: 10.1186/bcr969. Epub 2004 Dec 7. [PubMed:15642164]
  2. Trosken ER, Fischer K, Volkel W, Lutz WK: Inhibition of human CYP19 by azoles used as antifungal agents and aromatase inhibitors, using a new LC-MS/MS method for the analysis of estradiol product formation. Toxicology. 2006 Feb 15;219(1-3):33-40. doi: 10.1016/j.tox.2005.10.020. Epub 2005 Dec 5. [PubMed:16330141]
  3. Dowsett M, Jones A, Johnston SR, Jacobs S, Trunet P, Smith IE: In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res. 1995 Dec;1(12):1511-5. [PubMed:9815951]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Jeong S, Woo MM, Flockhart DA, Desta Z: Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro. Cancer Chemother Pharmacol. 2009 Oct;64(5):867-75. doi: 10.1007/s00280-009-0935-7. Epub 2009 Feb 7. [PubMed:19198839]
  2. Letrozole FDA label [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Jeong S, Woo MM, Flockhart DA, Desta Z: Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro. Cancer Chemother Pharmacol. 2009 Oct;64(5):867-75. doi: 10.1007/s00280-009-0935-7. Epub 2009 Feb 7. [PubMed:19198839]
  2. Raunio H, Rautio A, Gullsten H, Pelkonen O: Polymorphisms of CYP2A6 and its practical consequences. Br J Clin Pharmacol. 2001 Oct;52(4):357-63. [PubMed:11678779]
  3. Borrie AE, Rose RV, Choi YH, Perera FE, Read N, Sexton T, Lock M, Vandenberg TA, Hahn K, Dinniwell R, Younus J, Logan D, Potvin K, Yaremko B, Yu E, Lenehan J, Welch S, Tyndale RF, Teft WA, Kim RB: Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer. Breast Cancer Res Treat. 2018 Nov;172(2):371-379. doi: 10.1007/s10549-018-4910-z. Epub 2018 Aug 9. [PubMed:30094551]

Drug created on June 13, 2005 07:24 / Updated on December 07, 2019 14:28